摘要
目的 探讨EC序贯P剂量密集方案与TEC方案在乳腺癌新辅助化疗中的疗效及安全性.方法 选取我院收治的72例Ⅱ-Ⅲ期乳腺癌患者为研究对象,根据采用化疗方案的不同分为剂量密集组和TEC组,每组36例.剂量密集组采用EC序贯P剂量密集方案辅助化疗,TEC组采用TEC方案辅助化疗,比较两组患者的近期疗效、毒副反应及生存情况.结果 剂量密集组患者临床治疗总有效率为75.00％,TEC组患者临床治疗总有效率为72.22％,差异无统计学意义（P＞0.05）.剂量密集组患者2年无病生存率和总生存率分别为91.67％和100％,TEC组分别为86.11％和94.44％,组间差异无统计学意义（P＞0.05）.剂量密集组患者3-4级中性粒细胞下降发生率为8.33％,明显低于TEC组的30.56％,剂量密集组患者1-2级神经毒性和肌肉关节酸痛发生率分别为80.56％和66.67％,明显高于TEC组的36.11％和27.78％,差异有统计学意义（P＜0.05）.结论 EC序贯P剂量密集方案在乳腺癌新辅助化疗中的疗效与TEC方案相似,但毒副反应可耐受性更高,有利于延长患者的生存期,具有较高的临床推广价值.
Objective To compare the efficacy and safety of dose-dense EC followed by P regimen and TEC regimen in neoadjuvant chemotherapy for breast cancer.Methods 72 cases of stage Ⅱ-Ⅲ breast cancer treated in our hospital were selected as study subjects,and divided into dose-dense group and TEC group according to the different methods of chemotherapy,36 cases in each group.Dose-dense group received adjuvant chemotherapy with dose-dense EC followed by P regimen,TEC group received adjuvant chemotherapy with TEC regimen.Compared the short-term effect,toxic and side effects,and survival condition between two groups.Results The total effective rate of dose-dense group and TEC group were 75% and 72.22%,without statistically significant difference （P〉0.05）.2 years disease-free survival rate and overall survival rate of dose-dense group were 91.67% and 100%,and those of TEC group were 86.11% and 94.44%,without statistically significant differences （P〉0.05）.The incidence of class 3-4 neutropenia in dose-dense group was 8.33%,significantly lower than 30.56% in TEC group;the incidence of class 1-2 neurotoxicity,myodynia and arthrodynia in dose-dense group were 80.56% and 66.67%,significantly higher than 36.11% and 27.78% in TEC group,with statistically significant differences （P〈0.05）.Conclusion The efficacy of dose-dense EC followed by P regimen neoadjuvant chemotherapy is similar to TEC regimen,but the tolerance of toxic and side effects in dose-dense group is higher,help to extend the survival time of patients,with high clinical value.
出处
《国际医药卫生导报》
2016年第19期2995-2998,共4页
International Medicine and Health Guidance News
关键词
乳腺癌
剂量密集
新辅助化疗
Breast cancer
Dose-dense
Neoadjuvant chemotherapy
